Literature DB >> 33725850

Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report.

Siya Kong1,2, Han Chen1, Keting Huang1,2, Duochen Jin1,2, Guoxin Zhang1,2, Feng Ye1,2.   

Abstract

RATIONALE: Antibiotic resistance poses a challenge for Helicobacter pylori eradication treatment. Current guidelines strongly recommend avoiding repeated treatments with the same antibiotic to prevent the emergence of drug resistance. However, for penicillin-allergic patients with recurrent H. pylori eradication failures, avoiding repeated treatments with the same antibiotic severely limits the choice of treatment. PATIENT CONCERNS: A 47-year-old woman with a penicillin allergy for whom 2 previous levofloxacin and bismuth-based therapies had failed. DIAGNOSIS: H. pylori infection.
INTERVENTIONS: Agar dilution susceptibility testing and gene sequence analysis was performed to confirm levofloxacin susceptibility again. Therefore, we treated her with a 14-day regimen consisting of levofloxacin (500 mg once daily), furazolidone (100 mg twice daily), colloidal bismuth pectin (220 mg twice daily), and esomeprazole (20 mg twice daily). OUTCOMES: The patient was successfully treated with a third levofloxacin and bismuth-based regimen. LESSONS: Antibiotics included in previous failed therapies need not be eliminated if no antibiotic resistance is found on antimicrobial susceptibility testing.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33725850      PMCID: PMC7969298          DOI: 10.1097/MD.0000000000024915

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  19 in total

1.  The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection.

Authors:  John J Carothers; Michael G Bruce; Thomas W Hennessy; Michael Bensler; Julie M Morris; Alisa L Reasonover; Debby A Hurlburt; Alan J Parkinson; John M Coleman; Brian J McMahon
Journal:  Clin Infect Dis       Date:  2006-12-07       Impact factor: 9.079

2.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

3.  Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.

Authors:  Hideyuki Miyachi; Ikuya Miki; Nobuo Aoyama; Daisuke Shirasaka; Yuko Matsumoto; Masanori Toyoda; Toshifumi Mitani; Yoshinori Morita; Takao Tamura; Shohiro Kinoshita; Yoshie Okano; Shunichi Kumagai; Masato Kasuga
Journal:  Helicobacter       Date:  2006-08       Impact factor: 5.753

4.  Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection.

Authors:  Samuel Costa; João-Bruno Soares; Raquel Gonçalves
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-11       Impact factor: 2.566

Review 5.  Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Authors:  Samiksha Ghimire; Natasha Van't Boveneind-Vrubleuskaya; Onno W Akkerman; Wiel C M de Lange; Dick van Soolingen; Jos G W Kosterink; Tjip S van der Werf; Bob Wilffert; Daniel J Touw; Jan-Willem C Alffenaar
Journal:  J Antimicrob Chemother       Date:  2016-05-26       Impact factor: 5.790

6.  Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori.

Authors:  G Wang; T J Wilson; Q Jiang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori.

Authors:  Derrick Chen; Scott A Cunningham; Nicolynn C Cole; Peggy C Kohner; Jayawant N Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  Replicon typing of plasmids in environmental Achromobacter sp. producing quinolone-resistant determinants.

Authors:  João Pedro Rueda Furlan; Danilo Garcia Sanchez; Inara Fernanda Lage Gallo; Eliana Guedes Stehling
Journal:  APMIS       Date:  2018-11       Impact factor: 3.205

9.  Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.

Authors:  Jie Pan; Zhengchao Shi; Dingsai Lin; Ningmin Yang; Fei Meng; Lang Lin; Zhencheng Jin; Qingjie Zhou; Jiansheng Wu; Jianzhong Zhang; Youming Li
Journal:  Front Med       Date:  2020-01-03       Impact factor: 4.592

10.  Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.

Authors:  Muhammad Miftahussurur; Pradeep Krishna Shrestha; Phawinee Subsomwong; Rabi Prakash Sharma; Yoshio Yamaoka
Journal:  BMC Microbiol       Date:  2016-11-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.